At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Blacks and Exacerbations on LABA vs. Tiotropium (BELT)
In Brief
A Phase 3 clinical trial evaluating Tiotropium, Salmeterol, and 1 other intervention for Asthma. Completed, enrolled 1,070 participants across 13 sites.
Detailed Summary
We are doing this study to learn how genes affect the way that people, specifically Black people, respond to treatment for asthma. Recent studies suggest that people respond differently to some asthma medications (eg Serevent, Foradil). Some people feel better when they use these inhalers, but others may not, and some people get worse. It seems that this difference shows up more often in Blacks than in Whites, which is why we are looking for Black subjects for this study. In all people, this difference seems to depend on their genes or DNA. This study is comparing the use of long acting asthma medications (Serevent, Foradil) to Tiotropium (Spiriva) for the treatment of asthma. Spiriva is used to treat chronic obstructive pulmonary disease (COPD). This study will help to see if this medication is also useful for treating asthma and whether it works better for some people than the current asthma medications.
Study Details
Timeline
Interventions
Tiotropium bromide 18 mcg once daily for one year of treatment.
Salmeterol 50 mcg twice daily for one year of treatment.
Formoterol 12 mcg twice daily for one year